NCT00601159View on ClinicalTrials.gov

Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

September 30, 2010

Conditions
Metastatic Breast Cancer
Interventions
DRUG

gemcitabine and cisplatin

Cispaltin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 repeat every 3 weeks

Trial Locations (1)

+86200032

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT00601159 - Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC | Biotech Hunter | Biotech Hunter